Browse articles from EyeWorld.org related to dry eye. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Positive topline results for Phase 3 trial of drug for allergic conjunctivitis
➤ Phase 2 trial of progesterone topical gel for DED begins
➤ Breakthrough Device Designation granted to remote glaucoma management system
➤ Glaukos enters into licensing agreement for presbyopia treatment
➤ Increase in laser vision correction procedures continues
➤ Guide on climate change and eye health
➤ ASCRS events
➤ Topline data from a Phase 3 study investigating first-in-class DED drop
➤ Research initiative focuses on new glaucoma treatments
➤ Phase 2 trial for oral treatment of diabetic retinopathy begins
➤ New SLT trial recruiting study sites
➤ ASCRS news and events
➤ FDA approves enhanced monovision IOL
➤ Report: Demand for refractive surgery up amid pandemic
➤ Study: Antifibrotic activity of rho-kinase inhibitors
➤ Companies partner to explore nanoparticle applications for ophthalmic therapies
➤ ASCRS Journal Club on April 8
➤ Phase 2 clinical trial of minocycline for MGD
➤ Phase 2a study of drug-eluting contact lens for glaucoma
➤ Phase 1/2 results of RNA therapy for Usher syndrome, non-syndromic retinitis pigmentosa
➤ First regulatory approval for a therapeutic contact lens that treats ocular allergies
➤ Moist heat masks effective for signs, symptoms of dry eye, study finds
➤ ASCRS Journal Club on April 8
➤ FDA accepts IND for presbyopia-correcting eye drop
➤ Pivotal study of new tech against gold standard patching treatment of amblyopia
➤ Topline results from trial to reverse pharmacologically induced mydriasis
➤ Pivotal study of fixed-combination tropicamide/phenylephrine product for mydriasis
➤ ASCRS introduces new Richard L. Lindstrom Lecture
➤ FDA accepts NDA for fixed-combination mydriatic agent
➤ NDA accepted by FDA for dry eye nasal spray
➤ NDA submitted for drop to treat presbyopia
➤ Study to assess outcomes of ab interno canaloplasty
➤ Largest study of glaucoma genetics published
➤ Iridex and Topcon enter into strategic agreement
➤ COVID-19 vaccine update
➤ ASCRS Journal Club on March 11
➤ 2021 ASCRS Annual Meeting update
➤ FDA approves new monofocal IOL
➤ First patient dosed in Phase 2 trial for investigational DED therapy
➤ Phase 2a trial initiated for add-on wet AMD therapy
➤ Enrollment complete for Phase 3 studies of investigational dry eye drug
➤ Update from two Glaukos trials
➤ Study: Remote monitoring with implantable IOP sensor affects clinical decision making
➤ ASCRS events
It’s important to address underlying conditions prior to cataract surgery, and dry eye is one such condition. Physicians must identify and treat it to ensure the tear film is optimized and measurements are correct.
With the COVID-19 pandemic temporarily closing practices around the country, many ophthalmologists had to figure out how to still communicate with and treat their patients. Several physicians commented on how the pandemic has affected their dry eye patient population and trends they have seen.
